Categories Earnings, Health Care
Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot
— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.
— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected
— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year
— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine
— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer
— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020
— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Earnings Preview: Home Depot’s Q3 report likely to reflect weak consumer demand
The US housing industry has been mostly resilient to headwinds like economic uncertainties so far this year. However, housing activity cooled in recent months as high mortgage rates and inflation
Take-Two Interactive (TTWO) will report Q2 2025 earnings this week, a few points to note
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) stayed red on Monday. The stock has gained 16% over the past three months. The gaming company is set to report its second
Earnings Summary: Highlights of Loews Corporation’s (L) Q3 2024 report
Loews Corporation (NYSE: L), a diversified company with businesses in the insurance, energy, hospitality, and packaging industries, on Monday reported higher revenue and profit for the third quarter of 2024.
